The Life Sciences team advised Akero Therapeutics (Nasdaq: AKRO) on its upsized underwritten public offering of 6,012,390 shares of common stock at a public offering price of $36.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 784,224 shares of common stock in this offering. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are approximately $216.4 million.
Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance to improve overall health. The company's lead product candidate, Efruxifermin (EFX), formerly known as AKR-001, is currently being evaluated in an ongoing Phase 2a clinical trial.
The Goodwin team was led by Mitch Bloom, John Mutkoski, Sam Zucker, Julie Tibbets, Gabriela Morales-Rivera, and Katherine Hand.
For more details, read the press release and articles in S&P Global, Seeking Alpha, and Reuters.
Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance to improve overall health. The company's lead product candidate, Efruxifermin (EFX), formerly known as AKR-001, is currently being evaluated in an ongoing Phase 2a clinical trial.
The Goodwin team was led by Mitch Bloom, John Mutkoski, Sam Zucker, Julie Tibbets, Gabriela Morales-Rivera, and Katherine Hand.
For more details, read the press release and articles in S&P Global, Seeking Alpha, and Reuters.